Navigation Links
International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia
Date:10/13/2011

JERUSALEM, Oct. 13, 2011 /PRNewswire/ -- IDenta Corp. (OTC: IDTA) CEO Yaacov Shoham today announced the following order.

Mr. Shoham stated, "We are succeeding in making sales in many new markets, including Australia-a most important market for IDenta's different products.

We have received an order for 2000 detectors from the Australian representative GK Solutions Pty Ltd., http://www.gksolutions.com.au/

In the past several months we have been in continuous contact with this Australian company, developing the best strategy to penetrate the different Australian markets. Our different products have been presented to many different Australian agencies (Homeland Security, etc.) and the reaction has been very positive. We are expecting to receive substantial orders from some of those agencies in the next budget (starting January 2012) especially from Australian Customs, the AFP (Australian Federal Police), New South Wales Police, Western Australian Police, Etc.

Many of the Australian agencies have tested our detectors in the past several months. The tests were very successful, therefore we (IDenta and GK) are confident that we are finally able to penetrate these most important Australian markets."

IDenta's entire product line may be found at www.identa-corp.com, www.drugsdetector.com and www.identa.biz

ABOUT IDENTA

Since 2003, IDenta Corporation has been recognized as a worldwide leader in the development of proprietary on-site drug, drug precursor and explosive detection kits. IDenta develops, manufactures and distributes products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

DISCLAIMER

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

For Investor Relations, lobbying interests or information concerning IDenta's products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com, www.drugsdetector.com, www.identa.biz, www.identa-corp.com.


'/>"/>
SOURCE IDenta Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
2. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
3. VacChina 2011 International Conference Meets in Shanghai This November
4. Security First International Holdings Inc. (Pink Sheets: SCFR): Our Quantum Resonance Analyzer Draws In A Big Crowd At The Testing Site
5. Max Neeman International ISO 14155: 2011 Certified for Medical Device Trials
6. Rock Creek Pharmaceuticals Offers International Shipping Options for Anatabloc™
7. 2011 International Conference on TomoTherapy (ICT) Highlights Widespread Acceptance of the Benefits of Daily Image-Guided IMRT
8. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
9. Definiens to Introduce New Generation of Products for Tissue-based Biomarker Research at the International Definiens Symposium
10. Chindex International, Inc. to Attend Nomura Healthcare Corporate Day
11. International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor the ... brings together top non-profit leaders, ultimate organizations, and coaches from around the US. The ... Area Disc Program Director of Youth and Education, describes this year YUCC as “an ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... ... 2016 , ... Give To Cure today announced that it is ... Give To Cure’s campaign that is crowdfunding clinical trials to help find cures faster ... through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among ...
Breaking Medicine News(10 mins):